ClinicalTrials.gg
CompletedNCT07317622Updated Jan 5, 2026

Effectiveness of a Brief Intervention for Bereaved Individuals

An interventional study of Facilitating Grief in Bereavement, sponsored by Servicio Canario de Salud. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Servicio Canario de Salud · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Oct 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Grief is the response to the death of a loved one. The loss of a loved one requires a grieving process that allows one to adapt to the new situation. The main objective of this study is to identify people in a situation of bereavement who attend nursing consultations in Primary Care on the island of Tenerife, through opportunistic recruitment with the aim of carrying out a brief nursing intervention on those who are classified as being in a situation of bereavement.

Read the detailed description

Grief is a complex and multidimensional process involving an emotional, cognitive, behavioral, and spiritual response to loss. From a nursing perspective, it is recognized as important to address this phenomenon holistically, considering the personal, familial, and sociocultural factors that influence its experience. According to the NANDA-I taxonomy, the diagnoses of maladaptive grief, risk for maladaptive grief, and readiness for enhanced grief fall under the coping/stress tolerance domain, reflecting the need for interventions focused on adaptation and emotional well-being.

In the healthcare setting, the primary care nurse plays a key role as the professional who maintains continuous contact with individuals and their families. The nursing intervention Facilitating Grief (NIC 5290) integrates activities such as active listening, therapeutic communication, reality orientation, music therapy, and the use of personal journals. These strategies promote emotional expression, life reorganization, and personal resilience. The use of standardized instruments (such as the Psychosocial Nursing Diagnoses Questionnaire) allows for the identification of risk factors and the planning of evidence-based care.

The proposed secondary objectives are the following: To detect risk factors that may predispose patients attending nursing consultations to maladaptive grief; To understand the usual management of people in a state of grief and their care needs; To design a brief nursing intervention in Primary Care nursing consultations and evaluate its effectiveness; and To raise awareness among Primary Care professionals about grief, its characteristics and approach, through training activities.

The null hypothesis (H0) of this research establishes that, in the studied population, brief nursing intervention does not produce a significant effect on the effectiveness of nursing care in accompanying grief or in preventing its complications.

02

Conditions studied

  • Bereavement

Keywords

  • bereavement
  • primary care nursing
  • community health nursing
03

In context

Lead sponsor

Servicio Canario de Salud is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be over 18 years old.
  • That they answer affirmatively to at least one of the following two questions:

Have you lost a loved one in the last year? Are you grieving the loss of a loved one?

- After being informed, agree to participate in the study and sign the .

Exclusion criteria

Exclusion Criteria:

  • People with language barriers.
  • People with cognitive impairment.
  • People with severe sensory deficits.
  • People with a history of anxiety disorders, diagnosed severe depression, or other problems (emotional, coping, etc.) that prevent them from participating in the collection of information necessary for this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Participant group

    Other: Facilitating Grief

Interventions

  • OtherFacilitating Grief

    This intervention, called "Facilitating Grief," begins with an initial nursing assessment using the Psychosocial Nursing Diagnosis Questionnaire (PSDQ), the Relationship Continuity Scale, and an exploration of manifestations related to the grief situation. This initial assessment lasted between one and three hours, depending on the individual. Subsequently, a personalized care plan was established using standardized language, applying the most appropriate interventions for each person experiencing grief. The intervention also includes follow-up through several subsequent consultations (between two and four), in which the care plan is reviewed and adjusted according to the individual's progress, and a final assessment to evaluate the results achieved.

06

What researchers measure

Primary outcomes

  1. Number of participants with Clinical manifestations of their grief situation

    According to the defining characteristics and risk factors of NANDA-I grief diagnoses

    Time frame: Pre and post intervention (at 4 or 6 weeks)

  2. Number of participants with Continuity of Bonds internalized or externalized

    The Continuity of Bonds Scale is an instrument that explores how the bereaved person continues to relate symbolically and emotionally to the deceased. It consists of 16 questions with two dimensions (internalized, 10 items, and externalized, 6 items). Responses are on a Likert scale from 1 to 4 points (1 = "not at all", 4 = "constantly").

    Time frame: Pre and post intervention (at 4 or 6 weeks)

  3. Number of participants with Pssychosocial problems

    The Psychosocial Nursing Diagnosis Questionnaire (PSDN) is a validated tool. This instrument includes up to 28 psychosocial nursing diagnoses, grouped into six dimensions: health perception/management, behavior/social interaction, emotional/self-perception, caregiver burden, loss/grief, and body image disturbance. It uses Likert-type scales and dichotomous questions to grade responses, assigning different diagnostic labels based on predefined combinations.

    Time frame: Pre and post intervention (at 4 or 6 weeks)

  4. Number of participants willing to improve their grief

    Nursing diagnosis " Readiness for enhanced grief " (Yes/No) and presence/absence of the following defining characteristics: Desire to carry on the deceased's legacy; Desire to engage in previous activities; Desire to enhance grief coping; Desire to enhance forgiveness; Desire to enhance hope; Desire to enhance personal growth; Desire to enhance sleep-wake cycle; Desire to integrate feelings of anger; Desire to integrate feelings of despair; Desire to integrate feelings of guilt; Desire to integrate feelings of remorse; Desire to integrate positive feelings; Desire to integrate positive memories of the deceased; Desire to integrate the possibilities of a happy life; Desire to integrate the possibilities of a meaningful life; Desire to integrate the possibilities of a purposeful life; Desire to integrate the possibilities of a satisfying life; Desire to integrate the loss; Desire to invest energy in new interpersonal relationships.

    Time frame: Pre and post intervention (at 4 or 6 weeks)

  5. Number of participants with maladaptive grief

    Nursing diagnosis " maladaptive grief " (Yes/No) and presence/absence of the following defining characteristics: Anger; Anxiety Decreased performance in life roles; Depressive symptoms; Distress over the deceased; Excessive stress; Feelings of emptiness; Avoidance of grief Non-acceptance of death; Persistent painful memories; Preoccupation with thoughts about the deceased person; Rumination (obsessive ideas) about the deceased person; Searching for the deceased person; Self-blame.

    Time frame: Pre and post intervention (at 4 or 6 weeks)

  6. Number of participants at risk of maladaptive grief

    Nursing diagnosis " risk of maladaptive grief " (Yes/No) and presence/absence of the following defining characteristics: Difficulty dealing with recurrent crises; Excessive emotional disturbance; Inadequate social support; Anxious attachment (in their relationship with others); Avoidant attachment (in their relationship with others).

    Time frame: Pre and post intervention (at 4 or 6 weeks)

Secondary outcomes

  1. Number of participants with chronic health problems

    Dichotomous variables (Yes/No)

    Time frame: Pre-intervention

  2. Number of participants receiving pharmacological treatment

    Dichotomous variables (Yes/No)

    Time frame: Pre-intervention

  3. Number of caregiver participants

    Dichotomous variables (Yes/No)

    Time frame: Pre-intervention

  4. Time since death

    Continuous quantitative variable (days, months, years)

    Time frame: Pre-intervention

  5. Cause of death

    Nominal qualitative variable

    Time frame: Pre-intervention

07

Study locations

1 site
  • Gerencia Atención Primaria Tenerife
    Santa Cruz de Tenerife, 38003, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Feb 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartActual
Oct 14, 2024
Primary completionActual
Feb 22, 2025
CompletionActual
Apr 22, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07317622
Lead sponsor
Servicio Canario de Salud
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Oct 14, 2024
Primary completion
Feb 22, 2025
Completion
Apr 22, 2025
Last update
Jan 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion